Sopherion completes enrollment in Phase III breast cancer study
Sopherion Therapeutics, a developer and marketer of anticancer therapies, has completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin, or Myocet, in metastatic HER-2-overexpressing breast
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.